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With the development of shorter-lived, organ-
specific radiopharmaceuticals, much of the manufac-
ture and quality control of these products have 
shifted from commercial manufactures to individual 
nuclear medicine laboratories. Recognizing this fact, 
the Nuclear Regulatory Commission (NRC) is en-
couraging quality assurance by proposing that "an 
authorized physician may permit technicians and 
other paramedical personnel to perform the prepara-
tion and quality control testing of radiophar-
maceuticals ... " (I). 
Cohen (2) has catagorized pharmaceutical con-
trols into chemical, biological, and physical. Figure I 
is a diagram of these controls. In each control a 
degree of purity is implied and is often determined by 
comparison to a standard. 
Chemical controls. 
A . Radiochemical purity. May be defined as that 
portion of the stated radionuclide in the stated 
chemical form. This can be assessed in the nuclear 
medicine laboratory by several techniques. It is ap-
plicable to Tc99m·pertechnetate compounds where 
the degree of tag to an organ-specific molecule must 
be evaluated. 
Radiochemical impurities may be demonstrated 
in those images where organs other than the target 
organ are visualized due to a free (unbound) radioac-
tive component of a labeled product. Visualization of 
thyroid on lung imaging (Fig. 2) or stomach with 
kidney (Fig. 3) and bone (Fig. 4) imaging are exam-
ples of these. Reagent "kits" labeled with 
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radionuclides should be at least 90% bound for op-
timum organ visualization. The assessment of 
binding can be accomplished in the laboratory 
by the use of gel filtration and/or thin-layer 
chromatographic techniques. Labeled reagent kits 
may contain small molecules (free Tc99m. 
pertechnetate), larger labeled molecules, and a 
reduced technetium fraction which is considered 
neither free nor bound to an organ-specific molecule. 
To determine the percentage of each component in 
this three-phase system by employing the gel filtration 
technique, 1-2 ,ul of the material is placed at the top 
of a gel column and eluted with a suitable solvent. 
Heavy molecules which do not enter the gel mesh-
work will be eluted first, after the void volume. Light 
molecules will follow several milliters later. Reduced 
technetium, if present, will bind to the gel and can 
be removed by oxidation with 0.1 % H 20 2 . This frac-
tion can be subsequently collected with additional 
volumes of solvent. The fractionated volumes are 
counted and quantitation of each component may be 
determined. 
Thin-layer chromatography employs the use of 
suitable media strips to which is spotted 5,ul of the 
radioactive material 2.5 cm from the bottom of the 
strip. The strip is dried and placed in a developing 
tank containing a suitable solvent system (Fig. 5). 
The solvent is allowed to ascend the strip until the 
front is at approximately 14 cm. Solvent systems 
chosen provide for the bound material to remain ap-
proximately at the origin (point of application) while 
free activity migrates to the level of the solvent front. 
Using this method, Rf (reference factor) may be 
determined. These factors are ratios of distance 
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Fig. I-Diagram of the radiopharmaceutical controls. 
traveled by the radioactive entities to that traveled 
by the solvent front. Labeled molecule Rf are approx-
imately 0-0.1 while that of free species 0.8-1.0. Sol-
vent systems may be single or multiple components 
and provide for good separation of labeled molecules 
and free ionic species. 
Strips are removed from developing tanks, air 
dried, and analyzed for quantitation of components 
in the sample. Strips may be cut into I cm widths and 
placed into gamma well counters to determine 
presence and, therefore, identity of activity on the 
strip. The origin (2.5-3 .5 cm) of acceptable 
radiopharmaceuticals contains 90% of the counts. A 
radiochromatogram well adapter can be used and is 
less time consuming (3). Radioscanchromatographs 
can provide this information by producing a graph 
with peaks of activity demonstrating location and 
quantitation of radioactive components. 
Figure 6 is a chromatograph of Tc99m-
Polyphosphate® (New England Nuclear) used as the 
bone scanning agent in Figure 4. The chromatograph 
demonstrates activity at the origin representing 
Fig. 2-1'"-macroaggregated albumin (Abbott) lung image 
demonstrating thyroid uptake of free radioiodine. 
Fig. 3-Tc••m-Renotec (Squibb) kidney image demonstrating 
stomach uptake of free Tc••m-pertechnetate. (Image provided 
courtesy Dr. H. T. Haden, McGuire VA Hospital, Richmond, Va.) 
Tc99m-pertechnetate bound to phosphate complexes, 
activity between origin and solvent front demonstrat-
ing reduced pertechnetate and/ or labeled metabo-
lized phosphates, and a second but less prominent 
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Fig. 4-Tc••m-Polyphosphate® (New England Nuclear) bone im-
age demonstrating stomach uptake of free Tc••m·pertechnetate. 
Increased activity in liver probably associated with a reduced 
technetium species in blood pool. 
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Recommended Chromotography Sol vents 
Rf 
Preeorotion Solvent BTc FTc 
Tc99m (Sn ) DTPA Acetone 0 . 0 l. 0 
Butyl acetate o.o 0 . 8 
Tc99m (Sn ) Gluco -
heptonate M.E . K. 0.0 1.0 
· Tc99m - HSA Methanol , 85% 0 . 0 0.8 
Tc99m - MAA Methanol, 85% 0.0 0.8 
Tc99m - Pol yphosphate Acetone 0.0 1.0 
Butyl acetate 0.0 0.8 
Renotec * Butanol: Ethanol: Water 0 . 1 0.7 
(2 :2: 1) 
Tc99m - Sulfur Colloid Methanol, 85% 0. 1 l. 0 
*Eastman TLC Cellulose #6064 media; all others, Gelman !TLC 
Type SG 
Fig . 5-Chromatography solvent systems recommended for the 
determination of bound (BTc) and free (FTc) components of 
technetium-99m kit preparations. Each system provides reproduci-
ble Rf values used in the identification and quantitation of each 
component. 
peak at the solvent front demonstrating free 
pertechnetate. 
Figure 7 compares the chromatographs ofTc••m_ 
Polyphosphate® (NEN) to that of Osteoscan® (Proc-
tor and Gamble). Technetium-99m-pertechnetate ob-
tained from a 400 millicuries fission Mo""-Tc99m 
generator was used to prepare each of the above bone 
imaging agents. The Tc••m-Polyphosphate® chromat-
ogram demonstrated 98.5% of the pertechnetate 
bound to the phosphate complex. With Osteoscan®, 
the chromatograph demonstrated a reduced and/ or 
labeled metabolized phosphate component of approxi-
mately 40%. The manufacturer claimed that the ni-
trogen atmosphere in the vial was lost through the 
rubber closure with oxidation of the Sn(II) reducing 
agent. (Recently the manufacturer has adopted a 
butyl rubber closure which has resolved this problem.) 
Figure 8 is a chromatograph of Tc••m-Sn-
Glucoheptonate® (NEN). With methyl ethyl ketone 
(MEK) solvent, peak activity was found at the 
origin corresponding to the bound component. No 
free pertechnetate was demonstrated. The manu-
facturer claimed the material may be subject to col-
loid formation with some resultant localization of 
activity in the liver. The material was chromato-
gramed in a physiologic saline solution demonstrat-
ing no colloid at the origin. 
B. Carrier amount. May be defined as stable or 
long-lived isotopes of the nuclide present at the time 
of administration of the radiopharmaceutical. Car-
rier, if present in large quantities, alters the distribu-
tion of the nuclide in vivo or adds to radiation burden 
if it is radioactive. Manufacturers prepare com-
pounds that are "carrier-free." This has come to 
mean that no other isotope of the nuclide has been in-
tentionally added. 
C . Buffer amount. The pH of radiophar-
maceuticals should be adjusted to provide for stable 
complexes as well as physiologic suitability. Most 
radiopharmaceuticals are adjusted in the range of pH 
4.0 to 8.8. 
D. Total ions concentrations. Radiochemical 
solutions after production may contain various 
metals or metaloids as contaminants. These contami-
nants may be imparted from apparatus and reagent 
materials even if very pure. Complexation of the 
radiochemical with these traces give chemically un-
stable radioactive solutions. A standard of 80µg / ml 
of these ions has been set; however, the current state 
of the art is to prepare products with less than 
lµg / ml. 
Of the potential nonradioactive ionic impurities 
present in Tc••m-pertechnetate eluent, aluminum [Al 
(III)] has produced the most concern. Toxicology of 
Al (III) of potential doses administered appears 
minimal (Fig . 9); however, it has been reported to 
cause flocculation of Tc99m-sulfur colloid prepara-
tions as well as agglutination of red blood cells during 
the labeling process (4). Current NRC standards limit 
the presence of this ion to IOµg (fission Mo"") and 
20µg (activation Mo"") per milliliter of generator 
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Fig. &-Chromatograph ofTc09m-Polyphosphate® used to produce 
bone image in Figure 4 demonstrates bound, reduced, and free 
components of the radiopharmaceutical. 
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COMPATIBILITY OF KIT SOURCE AND RADIONUCLIDIC BINDING EFFICIENCY 
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Fig. ?-Comparison of chromatographs obtained after preparation of two commercially available bone imaging agents; Tc" m-Polyphos-
phate® (New England Nuclear), Tc••m-Osteoscan® (Proctor and Gamble) . 
eluent. This represents a more stringent requirement 
from a previous 500µg Al (III)/10 millicuries Tc99m-
pertechnetate limitation. 
To determine at what concentration of Al (III) 
flocculation of sulfur colloid would occur, Al (Ill) 
solution was prepared by dissolving 99+% aluminum 
metal in HCI. Aluminum (III)-Tc99m-pertechnetate 
solutions were prepared such that Al (III) concentra-
tion ranged from lOµg/ml to lOOOµg/ml of Tc99m-
pertechnetate in saline (Fig. 10). A control using Al 
(III) free pertechnetate was also prepared. Tech-
netium-99m-sulfur colloid (Squibb) were prepared 
by standard methods incor,porating each of the Al 
(III)-Tc99m-pertechnetate solutions as the radioactive 
source. Final sulfur colloid volumes were 8 ml giving 
resultant Al (III) concentrations of O to 12.50 mg%. 
Aluminon reagent (aurin-tricarboxylic acid) test 
strips (NEN) were evaluated for suitability in the 
detection of Al (Ill) contamination at levels as-
sociated with sulfur colloid flocculation (Fig . 11 ). 
Colloid aggregation was determined by placing 0.1 
ml of each sample on a standard hemocytometer 
chamber and observation under light microscopy 
(Fig. 12). 
Two hundred microcuries (0.2 ml) of each of the 
sulfur colloid preparations were injected into 250 g 
female Sprague-Dawley rats via a femoral vein . Scin-
tiphotos were obtained using the Searle Radio-
graphies .Pho-Gamma HP camera fitted with a pin-
hole collimator to demonstrate distribution of the 
radiocolloid (Fig. 13). 
Preparations of sulfur colloid from O to 0.63 
mg% Al (Ill) demonstrated no aggregation. Alumi-
non test papers demonstrated an increase in the pres-
ence of Al (III) with each increase in ion concen-
tration . Scintiphotos of test animals demonstrated 
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BINDING EFFICIENCY Tc99m-Sn-GLUCOHEPTONATE (N.E.N.) 
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Fig. 8-Chromatographs obtained following development of Tc••m-Sn-Glucoheptonate® (New England Nuclear) in two solvent systems. 
Upper chromatograph demonstrates absence of free pertechnetate. Lower chromatograph demonstrates absence of colloid. 
distribution of radiocolloid to liver with no uptake in 
lung. At 0.94 mg% Al (III), some colloid aggregation 
was present with minimum uptake of colloid in the 
lung of test animal. At 1.56 mg% Al (III), aggregate 
size became critical with scintiphotos demonstrating 
significant quantities of radiocolloid in lung. Lung 
uptake of radiocolloid increased at 3.13 mg% Al (III). 
Test materials containing 6.25 mg% and 12.50 mg% 
Al (III) demonstrated larger aggregates; however, 
these materials were not administered to test animals 
because aggregates would be limited to the inside 
diameter (254µ) of the 25 G needle. 
Liver, lung, and spleen from each test animal 
were excized and counted using a Picker well counter. 
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TOXICOLOGY ALUMINUM CONTAMINATION IN 
PERTECHN ET ATE 
A.E.C. LIMIT - lOµg./ml. NaTc04 
I. V. LD50 OF ALUMINUM (AS AICJ 3) IN MICE IS 
79 mg./Kg. (EQUIVALENT TO ABOUT 20 mg. 
ALUMINUM/Kg.) 
I.V. LD2 OF ALUMINUM (AS AICl 3) IN MICE IS 
55 mg./Kg. (EQUIVALENT TO 14 mg. ALUMINUM/Kg.) 
Fig. 9-Nuclear Regulatory Commission (AEC) allowable limit 
for aluminum ion contamination in Tc00m-pertechnetate. Limit is 
within a margin of safety for administration to man. 
Ratios of counts for liver: lung and liver: spleen were 
calculated (Fig. 14) and demonstrated good correla-
tion with Squibb Institute reports for the control 
material. At Al (III) concentration of 0.13 mg% to 
0.94 mg%, there was a general increase in liver: lung 
with a corresponding general decrease in liver: spleen. 
Sulfur colloid used in liver imaging vary in size from 
mµ to I µ. Up to 15% of the material may normally 
localize in bone marrow attributable to the smaller 
end of colloid size range. With increasing concentra-
tions of Al (III), smaller colloid may aggregate 
providing for more liver localization. Similarly, as the 
colloid size continues to increase, more of the 
material may localize in spleen, which is capable of 
phagocytizing colloid larger than that by liver. 
At the critical concentration of 1.56 mg% Al 
(Ill), liver: lung was 0.32: I demonstrating on a per-
gram basis three times the activity of radiocolloid in 
lung as compared to liver. At 3 .13 mg% Al (III), ac-
tivity in the lung increased to 16 times that of liver. 
~ µ.g, Al + 3Lm1. Tc99m04 {mg. %i µ.g. Al + 3/ ml. Kit* (mg. %) 
10 10 (1.0) 1.25 (0.13) 
25 25 (2 .5) 3.13 (0.3 1) 
50 50 (5 .0) 6.25 (0.63 ) 
75 75 (7 ,5 ) 9.38 (0.94) 
125 125 (12.5) 15.63 (1.56) 
250 250 (25.0) 31.25 (3 .13 ) 
500 500 (50.0) 62.50 (6.25) 
1000 1000 (100.0) 125.00 (12.50) 
* FINAL PREPARATION = 8 ml. 
Fig. IO-Concentration of aluminum ion in radioactive solutions. 
Center panel expresses aluminum concentration present in Tc00m-
pertechnetate. Third panel expresses aluminum concentration 
present following preparation of sulfur colloid kit. 
Aluminum Ion Spot Test 
Aluminon Reagent Paper 
NaTc99mo 4 
Control 
125JJgAl+3 /ml. 
250JJgAl+3 /ml. 
500pgA1+3 /ml. 
1000pgAl+3 /ml. 
Fig. I I-Change in aluminon spot test with increasing concentra-
tion of aluminum ion. 
In conclusion, the Aluminon test papers were 
adequate in detecting Al (III) concentration, and the 
maximum allowable concentration of Al (III) in 
Tc••m-pertechnetate was found to be 75µg/ml. The 
current standard is well within this value. 
Biological Controls. The United States Phar-
macopeia (USP) specifications for all parenteral 
products includes the absence of viable forms of 
bacteria, viruses, yeast, and molds as well as 
pyrogenic substances. Therefore, radiopharmaceuti-
cals administered parenterally must also be of this 
quality. 
A. Sterility. Many of the radiopharmaceuticals 
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Tc99m - SC 
Fig. 12-Effect of increasing concentration of 
aluminum ion on colloid aggregation. Magni-
fication is IOX. 
Representative of 
0 -0.63mg.0/oAl+3 
l.56mg.0/oAl+3 
6.25 mg.0/oAl+3 
~ 
50JJ 
0.94mg.0/oAl+3 
3.13mg.0/oAl+3 
12.50mg.0/oAl+3 
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Omg.0/0A1+3 
0.31mg.0/oAt+3 
0.94mg.0/oAt+3 _ 
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0.13mg. 0/oAl+3 
0.63mg.0/oAt+3 
1.56 mg. 0/o A1+3 
Fig. 13-Effect of increasing con-
centration of aluminum ion on 
radiocolloid distribution in rat. 
Anterior views obtained with 
Searle Radiographies-HP gamma 
camera fitted with a pin-hole 
collimator. Each image represents 
the accumulation of 100,000 
counts. 
3.13mg.0/oAl+3 
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Effect of Al+3 Content in Tc99m - Sulfur Colloid on 
Distribution Ratios* in Rat Organs (per gram wt.) 
.!!19· % Al+3 Liver:Lung Liver: Spleen 
0 4.73: l 1. 23:l 
0. 13 6.73:l 6.43: l 
0.31 5,23:l 4.77: l 
0.63 3.46: l 1.83:l 
0.94 4.81:l 1.59:l 
l.56 0.32:l 1.16:l 
3.13 0.06: l 0 . 37:l 
* 20 min. post-injection (i.v.) 
Fig. 14-Ratios ofliver:lung and liver:spleen counts obtained from 
excized rat organs. Ratios are expressed per-gram weight of organ. 
used as diagnostic agents in nuclear medicine are in-
tended for parenteral administration. Phar-
maceuticals of this type must meet USP requirements 
in that they are sterile, apyrogenic, and of acceptable 
pH (5). 
Methods of sterilization vary and selection is 
dependant upon stability of the compound and its 
label. Terminal sterilization in an autoclave and 
membrane filtration are two of the more commonly 
used methods employed to sterilize radiophar-
maceuticals. With each of the above methods, 
however, samples must be taken and tested to con-
firm sterility. 
The USP method requires innoculation of the 
radiopharmaceutical into fluid thioglycolate and 
Soybean-Casein Digest medias. A 7-day incubation 
period at 30 to 35 °C with fluid thioglycolate and 20 to 
25°C with Soybean-Casein Digest without evidence of 
viable organisms indicates a sterile preparation. It 
becomes apparent that activity of radiopharmaceuti-
cals with short physical half-lives would significantly 
decay before the product was approved for clinical 
use. Under this circumstance, the dilemma of whether 
to administer the preparation may be minimized if 
asceptic technique were employed and previous 
materials tested after-the-fact demonstrated sterility. 
Work by Deland and Wagner (6) has shortened 
the determination of sterility to within acceptable 
time for short-lived nuclides. Test materials are in-
noculated in thioglycolate broth containing C 14 
glucose. Viable organisms, if present, would 
metabolize the labeled sugar to C140 2 which is 
detected and recorded, demonstrating the presence of 
microbial contamination. This procedure, although 
not an official test, has reduced lag time from days to 
1-3 hours. 
B. Apyrogenicity. Pyrogens of microbial origin, 
are mucopolysaccharide molecules present as the 
result of bacterial, viral, fungal, or yeast contamina-
tion. The substances are heat-stable and therefore 
resistant to destruction by terminal sterilization. 
When administered by some injection route, they 
may produce in man such symptoms as mono-or 
biphasic fever, chills, malaise, mild to moderate pain 
in the joints, and leukopenia, or other less well-defined 
clinical signs, such as apprehension, pallor, and sub-
sternal oppression (7). Sensitivity of the human body 
to administration of pyrogens by the intrathecal 
route is such that the biologic insult of this type in-
creases 4000-fold as compared to the intravenous 
route (8). 
The USP method for the detection of pyrogens 
relies upon rectal temperature change in the pre- to 
post-innoculated rabbit. Controls for the test are 
stringent and include: 
I. Use of healthy, mature rabbits each weighing 
not less than 1.5 kg that have maintained this 
weight for one week. 
2. Control temperature of each rabbit used does 
not vary by more than 1 °C from each other. 
No animal may be used with a control 
temperature exceeding 39.8°C. 
3. Animals must be housed individually, free 
from excitement, in an environmental tem-
perature that does not vary by more than 
± 3oc. 
4. Animals may not be used more than once 
every 48 hours. 
5. Animals may not be used before 2 weeks hav-
ing been given a test sample that was 
pyrogenic. 
6. Animals not used for pyrogen testing during a 
14-day period must be sham tested 1-3 days 
before use. 
7. Test material administered may not exceed 10 
ml. 
Test material is injected into the marginal ear 
vein of three animals. Rectal temperatures are 
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recorded at hourly intervals for three hours post in-
jection. If none of the test animals show an individual 
temperature rise of 0.6°C or more above its control 
temperature and if the sum of the temperature rises in 
all three animals does not exceed l.4°C, the test 
material meets the requirement of apyrogenicity. If 
the above criteria are not met, the test must be 
repeated with five rabbits. If not more than three of 
the eight rabbits show temperature rises of 0.6°C or 
more and if the sum of the eight temperature rises 
does not exceed 3.7°C, the product under test meets 
the requirement for apyrogenicity. 
Pyrogen testing by the USP method is difficult, 
time consuming, and generally not amenable to small 
laboratories. Cooper et al (9), have introduced an in 
vitro test based on the detection of endotoxin 
through gelation of Limulus polyphemus lysate 
prepared from blood amebocytes. Test results may be 
obtained in I hour which represents time saved with 
respect to short-lived nuclides. This test is signifi-
cantly more sensitive than the official test; however, it 
is subject to false positive results if the preparation to 
be tested contains Ca (II). The problems of adopting 
a more sensitive test must be justified in view of the 
fact that no documentation exists of pyrexia follow-
ing administration of materials found apyrogenic by 
the USP test. The question of how sensitive pyrogen 
testing must be deserves further investigation. 
C. Safety. With the administration of phar-
maceuticals in radioactive form, safety includes 
radiation-absorbed doses received by target and non-
target organs that are within acceptable limits . The 
product must also be nontoxic in doses administered 
with respect to formed cells in blood as well as organs 
to which the material will be distributed. 
D. Affinity. Radioactive compounds used in 
organ imaging localize by various physiological 
mechanisms . Control of the physiochemical 
characteristics of the radiopharmaceutical are needed 
to assure affinity of the product for target organs. 
Soloway and Davis ( I 0) reviewed radiophar-
maceuticals currently used for organ imaging and 
have catagorized their biological basis for localiza-
tion . In vitro quality control testing is essential to 
predetermine that organs of interest will be 
visualized . Poor affinity demonstrated by suboptimal 
images must frequently be repeated, therefore, neces-
sitating subsequent dosing with radionuclides and in-
creased radiation burden to patients. 
Perfusion lung imaging is dependant upon blood 
flow to that organ with capillary and terminal 
arteriolar blockage by radiolabeled particles. Parti-
cles for this purpose must be larger than that of red 
blood cells (7µ) to prevent arterial distribution after 
intravenous administration . To avoid an unneces-
sarily long, effective half-life in lung, as well as op-
timum patient safety, particles should be limited in 
size to 50µ. Particle size determination can be easily 
accomplished in the laboratory using light 
microscopy as a routine check. 
Images of liver and spleen are dependant upon 
blood flow to these organs with phagocytosis of 
radiocolloid by reticuloendothelial cells. Colloid of 
0.6µ and 1.0µ are necessary for localization in liver 
and spleen respectively. Although colloid may not be 
visualized by light microscopy, the test serves as a 
negative check for aggregates so large that they might 
localize in lung. 
Radioactive materials have been used to 
delineate special anatomic or biochemical compart-
ments . Labeled serum albumin has been used in the 
past for cisternography and currently for blood pool 
imaging. Care must be taken not to denature the 
protein by excessive labeling or chemical manipula-
tion. 
Stannous chloride [Sn{II)] has become a useful 
reducing agent in the preparation of technetium-
labeled radiopharmaceuticals . Yano et al {11), in 
studies with the bone imaging agent Tc99m-Sn-EHDP, 
found optimum molar ratio of Sn (11):EHDP for 
greater bone localization and rapid soft tissue 
clearance. They reported the importance in the order 
of combination of EHDP, Sn (II) and Tc99m-
pertechnetate such that poor formulation resulted in 
radiocolloid formation with localization in liver. 
Poor localization of other technetium products with 
significant uptake in thyroid has been noted when 
stannic chloride [Sn(III)] forms on crystal surfaces of 
the reducing agent. 
Physical Controls. 
A. Radioactive concentration. Refers to the ac-
tivity concentration of the product with respect to ac-
tivity per unit volume. Activity concentration can be 
easily determined using a dose calibrator. This instru-
ment has an overall accuracy of 5% and is designed to 
quantitate many of the more commonly used 
radionuclides. 
B. Radioactive purity. This term should be dis-
continued in favor of the more accurate term 
"radionuclide purity." It may be defined as that 
proportion of the total activity that is present as the 
stated radionuclide. 
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The NRC limit for Mo99 contamination has been 
set at I microcurie Mo99 per millicuries Tcgem_per-
technetate and 5 microcuries per dose of Tc99m-
pertechnetate. On a milligram basis the amount of 
Mogg necessary for a lethal dose or LD00 dose 
in test animals is large as compared to what can 
be eluted from an intact generator system (Fig. 15). 
However, on an equal activity basis using the MIRO 
system (12, 13), radiation burden from Mo99 is 35 
times greater as compared to Tc99m. It has also been 
demonstrated that parent Mo99 produced by neutron 
activation of Mo98 results in Cs134 contamination. 
Radioactive contaminants of Mo 99-Tc99m 
generator systems may be detected radiometrically . 
Molybdenum-99 emits 740 and 780 kev gammas as 
well as other less energetic photons. A 4 mm lead 
shield adapter inserted in the ion chamber of the dose 
calibrator would absorb all but 0.0002% of Tc99m 
gamma (140 kev) and 50% of Mo99 gamma (14). It is 
fortuitous that Mo 99 activity can be read directly on 
the Tc99m setting when the pertechnetate source is 
placed in the lead adapter. The method allows for 
quantitation of the Mo99 activity which should not 
exceed 0.1 % of the Tc99m activity. Cesium-134 emits 
605 and 796 kev gammas which penetrate the 4 mm 
lead shield and will be quantitated with the Mo99 
reading. 
In-House Preparation of Radiopharmaceuticals. 
Present day practice of nuclear medicine relies 
upon readily available organ-specific radiophar-
maceuticals. Exhaustive research of natural and man-
made radionuclides has resulted in a handful that 
demonstrate organ specificity with patient safety. As 
a result, research has been directed toward the label-
ing of molecules with radionuclides of near-ideal 
properties for organ selectivity. Technetium-99m 
having suitable physical, chemical, and biological 
properties enjoys an active role in organ imaging. 
Since 1961, many Tc9em-labeled compounds have 
been introduced which have broadened the 
diagnostic capabilities of nuclear medicine and/ or 
improved radiation burden as compared to 
previously used radionuclides. 
Much of this research has resulted in the com-
mercial availability of kit preparations where sim-
ple asceptic techniques are employed to produce the 
desired Tc99m radiopharmaceutical. With the com-
mercial availability of Mo99-Tc99m generators, daily 
delivery, or MEK extraction techniques, a con-
tinuous supply of Tc99m-pertechnetate is at hand for 
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I. V. LO 50 of Mo ( as Na2 MoO 4) in mice is obout 248 mg ./ Kg . 
(equi valent to 116 mg . Mo/ Kg. ) 
No effec t dose in mice is about 28 mg. / Kg . 
NRC Limit - 20µCi (total body burden ) 
Fig . 15-Nuclear Regulatory Commission maximum allowable 
limits for radionuclidic impurities in Tc••m-pertechnetate. 
the preparation of kits. The commercial availability 
of these tools has been a boon to many institutions 
which might not be able to provide this diagnostic ser-
vice. This availability, however, is not without cost, 
and newer formulations with clinical merit may 
take months before they become commercially 
available, thereby limiting diagnostic studies to cur-
rent available preparation. 
Radiopharmaceutical scientists (radiophar-
macist, radiochemist) have paralleled the growth of 
nuclear medicine consultants by providing efficacious 
radiopharmaceutical diagnostic agents. In-house 
preparation of radiopharmaceuticals by these in-
dividuals have allowed for the availability of newer 
agents in nuclear medicine practice. Institutions 
preparing radiopharmaceuticals are increasing, and 
those without this technical capability may benefit 
under a cost-sharing program ( 15). 
Several formulations are available for the 
preparation of the more routinely used imaging 
agents . The following are currently used at the 
Medical College of Virginia Hospitals . Drug-adverse 
reactions have not been reported for any of the 
products since clinical initiation. 
PREPARATION OF Tc99M-SULFUR COLLOID KIT (16) 
Solution A: 
To 100 ml of Sterile Distilled Water add: 
I. 400 mg Sodium Thiosulfate 
2. 750 mg Gelatin 
3. 850 mg Potassium Monohydrogen Phos-
phate (Dibasic) 
4. 200 mg Disodium Edetate 
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Stir and warm the mixture gently to dissolve the 
gelatin. After solution is complete, pipette ex-
actly 3 ml of the solution into each 30 ml serum 
vials. Seal the vials with rubber closures and 
aluminum caps (twice boiled in sterile distilled 
water for not less than 30 minutes and auto-
claved, wrapped in aluminum foil) and autoclave 
Solution A for 15 minutes at 20 PSIG pressure. 
Solution B: 
Sterilize 1-3 ml of exactly 0.5N HCI solution in 
serum vials by autoclaving for 15 minutes at 20 
PSIG pressure. 
Solution C: 
To 100 ml Sterile Distilled Water add: 
I. 1.20 g Sodium Hydroxide pellets 
2. 2.8 g Sodium monohydrogen phosphate 
Mix well until solution is complete. Do not 
autoclave. Sterilize by filtration using 0.22µ 
membrane filter. 
PREPARATION OF Tc99M MAA KIT (16) 
A. Prepare Albumin Sodium Acetate solution 
in distilled water such that it contains IO 
mg/ml of HSA, 100 mg/ ml of Sodium 
Acetate. Sterilize by membrane filtration 
(0.22µ size). 
B. Prepare Stannous Chloride solution in IN 
HCI such that it contains 5 mg/ ml of stan-
nous chloride. Sterilize by membrane filtra-
tion (0.22µ size). 
C. To an empty sterile serum vial containing a 
small magnetic stirrer mix 5 ml of Solution A 
with 19 ml of Sterile Water for Injection. 
Mix well. Add I ml of Solution B. The pH 
should be approximately 5.5. 
D. Macroaggregate the Albumin in the above 
solution in a water bath at 80°C± I for 12 
minutes with stirring. 
E. Cool and mix the aggregates well. Each ml 
of this preparation now contains: 
I. 2 mg HSA as aggregates (denatured) 
2. 200µg Stannous Chloride as hydroxide 
3. 20 mg Sodium Acetate as buffer 
F . Transfer under aseptic conditions I ml each 
of this solution to presterilized empty serum 
vials and store under refrigeration. 
PREPARATION OF Tc99M-LABELED HUMAN SERUM 
ALBUMIN (17) 
Materials: 
I. Kit (consists of 3 sterile pyrogen-free vials). 
Vial "A"-20 ml vial containing 0.85 ml 
of IN HCL with two I-inch lengths of Zr 
wire inserted through the diaphragm. 
Vial " B"-5 ml containing approximately 
I ml of HSA 25%. 
Vial "C"-5 ml vial containing approxi-
mately 2 ml of Sodium Bicarbonate 3.75% 
and Sodium Hydroxide 2.0% in sterile 
pyrogen-free water for injection . 
II. Lead pig (for housing 200 ml vial during 
procedure). 
III. D.C. power source with external leads 
adapted with alligator clips capable of 
providing 100 milliamps constant current 
at 3-5 volts . 
Procedure: 
I. Place vial "A" in lead pig; electrically in-
sulate the top of the container by covering 
top of lead pig and aluminum band with 
masking tape. Rubber diaphragm is left ex-
posed. 
II. To vial "A" aseptically add 5.5 ml of 
pertechnetate in normal saline (oxident 
free). Remove 5.5 ml air. 
III. To vial "A" aseptically add 0.1 ml ofHSA 
from vial "B" using a I ml TB syringe 
adapted with a 21 G needle. Flush syringe 
several times and remove 0.1 ml of air. 
IV. Immediately connect electrodes to power 
supply leads by means of alligator clips. 
V. Invert vial allowing contents of vial to 
come in contact with both electrodes. 
VI. Using circular motion gently agitate the in-
verted vial. Pass l 00 milliamps of current 
for exactly 42 seconds; continue to agitate 
vial inverted position for an additional 15 
seconds after electrolysis is completed. 
VII. Remove leads from electrodes, reinvert vial 
to upright position and allow vial "A" to 
incubate at room temperature for at least 
30 minutes. 
VIII . Add to vial "A" 1.2 ml of vial "C". 
Remove an equivalent amount of air. 
IX. Pass the product through a 0.22µ 
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membrane filter and collect in a sterile 
empty vial. 
Radiopharmaceuticals, whether prepared in-
house or obtained commercially, should be subjected 
to quality control testing. If the limitations of image 
interpretations are instrumentation, technique, ade-
quate patient history, and radiopharmaceutical 
quality, equal attention must be payed to all. 
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